| scholarly article | Q13442814 |
| P356 | DOI | 10.1034/J.1600-0609.2002.01549.X |
| P698 | PubMed publication ID | 12366710 |
| P2093 | author name string | Kenneth Nilsson | |
| Patrik Georgii-Hemming | |||
| Thomas Strömberg | |||
| Helena Jernberg-Wiklund | |||
| Helena Spets | |||
| Jan Siljason | |||
| P2860 | cites work | The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines | Q73535726 |
| Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism | Q73615079 | ||
| The Bcl-2 protein family: arbiters of cell survival | Q29618158 | ||
| The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications | Q35254984 | ||
| Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells | Q35670634 | ||
| Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. | Q36711639 | ||
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells | Q40972355 | ||
| Insulin/IGF-I Rescues Immortalized Brown Adipocytes from Apoptosis Down-Regulating Bcl-xS Expression, in a PI 3-Kinase- and Map Kinase-Dependent Manner | Q41007767 | ||
| Immunoglobulin synthesis in the human myeloma cell line U-266; expression of two immunoglobulin heavy chain isotypes (epsilon and alpha) after long-term cultivation in vitro | Q42820941 | ||
| Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. | Q48020559 | ||
| Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells | Q52826978 | ||
| Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas | Q59077136 | ||
| Type I insulin-like growth factor receptor activation regulates apoptotic proteins | Q71833567 | ||
| Interleukin-6 inhibits apoptosis of malignant plasma cells | Q72220182 | ||
| Fas antigen/APO-1 (CD95) expression on myeloma cells | Q73068666 | ||
| Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product | Q73106933 | ||
| Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status | Q73367164 | ||
| Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule | Q73416734 | ||
| P433 | issue | 2 | |
| P921 | main subject | multiple myeloma | Q467635 |
| apoptotic process | Q14599311 | ||
| P1104 | number of pages | 14 | |
| P304 | page(s) | 76-89 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | European Journal of Haematology | Q15765799 |
| P1476 | title | Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival | |
| P478 | volume | 69 |
| Q33930178 | Apoptosis of multiple myeloma. |
| Q39438698 | Arecoline decreases interleukin-6 production and induces apoptosis and cell cycle arrest in human basal cell carcinoma cells |
| Q36663554 | BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone |
| Q37197900 | BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice |
| Q28587037 | BCMA is essential for the survival of long-lived bone marrow plasma cells |
| Q43626781 | Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma |
| Q34029221 | Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression |
| Q55281764 | Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. |
| Q55456143 | Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. |
| Q36786053 | Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). |
| Q41767963 | CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells |
| Q53294841 | Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis |
| Q30436741 | Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors |
| Q54114538 | Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer. |
| Q34673555 | Ethanol extract of Forsythia suspensa root induces apoptosis of esophageal carcinoma cells via the mitochondrial apoptotic pathway |
| Q34104277 | Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells |
| Q91932452 | Gm40600 suppressed SP 2/0 isograft tumor by reducing Blimp1 and Xbp1 proteins |
| Q36292888 | Growth factors and antiapoptotic signaling pathways in multiple myeloma |
| Q36375146 | IL-6/STAT3 signaling pathway is activated in plasma cell mastitis |
| Q35833040 | Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. |
| Q40291972 | Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo |
| Q30433391 | KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation |
| Q46980065 | Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. |
| Q40560316 | Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. |
| Q89682913 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance |
| Q79798337 | Multiple myeloma |
| Q47131885 | Myocardin and Stat3 act synergistically to inhibit cardiomyocyte apoptosis |
| Q34380431 | Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice |
| Q35933953 | Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers |
| Q41708707 | Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma |
| Q40505607 | Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma |
| Q37523208 | R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. |
| Q35620266 | Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival |
| Q35830099 | The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis |
| Q38758658 | The protective effects of epigallocatechin gallate on lipopolysa ccharide-induced hepatotoxicity: an in vitro study on Hep3B cells |
| Q40586836 | The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells |
| Q38002487 | Through a glass less darkly: apoptosis and the germinal center response to antigen |
| Q91594513 | VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R-gp130 |
| Q101137057 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial |
Search more.